Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Thomson Reuters (TRI) Q4 Earnings: What Awaits the Stock?

by Zacks Equity Research

Let's see how things are shaping up for Thomson Reuters Corporation (TRI).

    Why Earnings Season Could Be Great for Allergan (AGN)

    by Zacks Equity Research

    Allergan (AGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

      Allergan (AGN) Q4 Earnings: What's in Store for the Stock?

      by Zacks Equity Research

      Allergan plc (AGN) will be reporting fourth-quarter 2016 earnings on Feb 8, before the market opens. Last quarter, the company delivered a negative earnings surprise of 7.00%.

        Arpita Dutt headshot

        Drug Stocks Rally on Trump Meet with Pharma Bigwigs

        by Arpita Dutt

        Pharma and biotech stocks were up as President Trump discussed a speedier drug approval process, lower regulations and corporate tax reforms.

          Allergan (AGN) Avycaz Label to Include New Phase III Data

          by Zacks Equity Research

          Allergan plc (AGN) announced that its supplemental new drug application (sNDA) for antibiotic Avycaz has been approved by the FDA. Allergan is looking to include new data from two phase III trials, RECAPTURE and REPRISE, in the drug???s label.

            Ironwood/Astellas Report Positive Phase III Data on Linzess

            by Zacks Equity Research

            Ironwood (IRWD) and partner Astellas reported positive top-line data from a phase III study on Linzess in adults with chronic constipation.

              Amgen Wins Favorable CHMP Opinion for Humira Biosimilar

              by Zacks Equity Research

              Amgen (AMGN) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion on the company's marketing authorization application (MAA) for ABP 501.

                Ironwood-Allergan Linzess Gets FDA Approval in Lower Dose

                by Zacks Equity Research

                Ironwood Pharmaceuticals, Inc. (IRWD) and partner Allergan plc (AGN) announced that the FDA has approved a lower dose strength of Linzess (linaclotide) ??? 72 mcg ??? for the treatment of adult patients with chronic idiopathic constipation (CIC).

                  Theravance's Infection Drug Vibativ Positive in TOUR Study

                  by Zacks Equity Research

                  Theravance Biopharma, Inc. (TBPH) recently released positive interim data from the ongoing TOURstudy evaluating how Vibativ (telavancin) is used to treat patients with bacteremia or infective endocarditis (IE).

                    Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint?

                    by Zacks Equity Research

                    Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report fourth-quarter and full year 2016 results on Jan 25.

                      Allergan (AGN) Rhofade Cream for Rosacea Approved in U.S.

                      by Zacks Equity Research

                      Allergan plc (AGN) announced that the FDA has approved Rhofade (oxymetazoline hydrochloride) cream for topical treatment of persistent facial erythema (redness) associated with rosacea in adults.

                        Should Value Investors Choose Allergan (AGN)?

                        by Zacks Equity Research

                        Allergan (AGN) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

                          Apricus (APRI) Stock Gains on Vitaros' Approval in Mexico

                          by Zacks Equity Research

                          Apricus (APRI) announced that Vitaros was approved in Mexico for the treatment of patients with erectile dysfunction.

                            Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?

                            by Zacks Equity Research

                            Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will be reporting fourth-quarter 2016 and full-year earnings on Jan 26.

                              Vertex Pharma (VRTX) Q4 Earnings: Stock Likely to Beat?

                              by Zacks Equity Research

                              We expect biotech company Vertex Pharmaceuticals, Inc. (VRTX) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Jan 25, after the market closes.

                                Allergan's Uterine Fibroids Candidate Positive in Phase III

                                by Zacks Equity Research

                                Allergan Plc (AGN) and European specialty pharma company Gedeon Richter reported encouraging results from a phase III study on their pipeline candidate, ulipristal acetate, in women with abnormal bleeding due to uterine fibroids.

                                  Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit

                                  by Zacks Equity Research

                                  Eli Lilly and Company (LLY) announced that it has received a favorable ruling in a lawsuit against generic drugmaker Teva Pharmaceutical Industries Limited (TEVA) related to the infringement of a vitamin regimen patent for its cancer drug Alimta.

                                    Arpita Dutt headshot

                                    Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again

                                    by Arpita Dutt

                                    Drug stocks were hit once again with President-elect Donald Trump's comments about the sector at his first news conference since his election in November.

                                      Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit

                                      by Zacks Equity Research

                                      Impax Laboratories, Inc. (IPXL) announced that it has filed an Abbreviated New Drug application (ANDA) with the FDA for a generic version of Sanofi's Aubagio (teriflunomide) tablets, 14 mg.

                                        Teva Falls on Disappointing 2017 Sales & Earnings Guidance

                                        by Zacks Equity Research

                                        Teva Pharmaceutical Industries Ltd. (TEVA) provided a weaker-than-expected sales and earnings guidance for 2017, seeing that its blockbuster multiple sclerosis drug, Copaxone, is reeling under competitive pressures.

                                          Allergan (AGN) Liletta sNDA Accepted for Review in the U.S.

                                          by Zacks Equity Research

                                          Allergan plc (AGN) and partner Medicines360, a nonprofit global women's health pharmaceutical company, announced that the FDA has accepted a supplemental New Drug Application (sNDA) for its marketed intrauterine system (IUS), Liletta.

                                            Allergan Natrelle Inspira Breast Implants Approved in the U.S.

                                            by Zacks Equity Research

                                            Allergan plc (AGN) announced that the FDA has approved Natrelle Inspira SoftTouch, a new medium firmness gel, or cohesive, implant option for breast reconstruction, augmentation or revision surgery.

                                              Cempra (CEMP) Gets CRL from FDA for Pneumonia Candidate

                                              by Zacks Equity Research

                                              Cempra (CEMP) announced that it received a CRL from the FDA relating to its new drug applications for oral and intravenous formulation of candidate solithromycin.

                                                Apple and Microsoft: Moving Opposite on Share Buybacks?

                                                by Zacks Equity Research

                                                Apple's (AAPL) spending on share buyback has decreased sequentially, while Microsoft's (MSFT) has increased in the third quarter of 2016.

                                                  4 Biotech Stocks with Bright Prospects in 2017

                                                  by Zacks Equity Research

                                                  Even as the drug pricing issue continues to plague the biotech sector, investors should find it safe to bet on these top-ranked biotech stocks that also have superb Style Score as markets roll into 2017.